|
Home | Medical-Newswire.Com:
|
(Medical-NewsWire.com, January 30, 2020 ) Growth in this market can primarily be attributed to factors such as the growing demand of personalized medicine, continuous support in the form of investments and grants from the government and private sectors, increasing number of R&D activities in pharmaceutical and biotechnology companies, and the increasing number of research activities involving humanized models. Increasing the production of monoclonal antibodies and rising demand for humanized rat models are expected to provide a wide range of growth opportunities for key players in the industry.
According to the new market research report "Humanized Mouse and Rat Model Market by Type (Genetic, Cell-Based (CD34, PBMC, BLT)), Application (Neuroscience, Hematopoiesis, Oncology, Immunology & Infectious Diseases) & End User (Pharmaceutical & Biotechnology Companies, CRO)) - Global Forecast", published by MarketsandMarkets™.
The Humanized Rat Models market is expected to reach USD 8.9 Million by 2022 from USD 5.9 Million in 2017, at a CAGR of 8.4% during the forecast period.
Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=131763955
The oncology segment commanded the largest share of the humanized mouse models market.
By application, the market is categorized into oncology, immunology and infectious diseases, neuroscience, hematopoiesis, toxicology, and other applications. Of all these application segments, oncology accounted for the largest share of the market in 2017. The increasing research activities and growing funding from various governments to carry out research studies on cancer are the major factors driving the growth of this segment.
Browse and in-depth TOC on " Humanized Mouse and Rat Model Market"
94 - Tables
42 - Figures
189 - Pages
Cell-based humanized mouse models to grow at the highest CAGR during the forecast period
By type, the humanized mouse model market is categorized into genetic and cell-based humanized mouse models. The cell-based humanized mouse models segment is expected to grow at the highest CAGR during the study period (2017–2022). The high growth of this segment can be attributed to the growing applications of cell-based humanized mouse models.
The cell-based humanized mouse models segment is further categorized into CD34, PBMC, and BLT humanized mouse models. In 2017, the CD34 models segment commanded the largest share of the cell-based humanized mouse models and is expected to grow at the highest CAGR during the forecast period.
Contract Research Organizations (CROs) to dominate the humanized mouse model market during the forecast period
By end user, the market is categorized into pharmaceutical & biotechnology companies, contract research organizations (CRO), and academic & research institutions. The contract research organizations (CROs) segment is projected to grow at the highest CAGR during the forecast period. Growth in this segment is largely due to the increasing number of pharmaceutical companies outsourcing their preclinical studies to contract research organizations (CROs).
North America dominated the market in 2017
Growth in this regional segment can be attributed to the increasing monoclonal antibody production, preclinical activities by CROs and pharmaceutical R&D, continued and responsible use of animals ensured by animal care organizations, growing biomedical research in the US along with government support for the development of protein drugs, and growing stem cell research in Canada.
Request Research Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=131763955
The major market players in the humanized mouse model market include The Jackson Laboratory (US), Taconic Biosciences, Inc. (US), Horizon Discovery Group plc (UK), genOway, S.A. (France), Charles River Laboratories (US), Harbour Antibodies BV (China), Hera BioLabs (US), Vitalstar Biotechnology Co., Ltd. (China), inGenious Targeting Laboratory (US), AXENIS S.A.S (France), Crown Bioscience, Inc. (US).
MarketsandMarkets™
Mr. Shelly Singh
1-888-600-6441
raviraj.tak@marketsandmarkets.com
Source: EmailWire.Com 
Source: EmailWire.com
|
|
|
|
